Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b

Background The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. Design and Methods In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The modulation of several genes and their biological consequence were verified in a panel of multiple myeloma cell lines and cells freshly isolated from patients by using polymerase chain reaction analysis and western blotting. Results Out of 38,500 human genes, we identified 140 and 574 up-regulated genes and 102 and 556 down-modulated genes at 2 and 6 h, respectively, with a significant presence of genes related to transcription regulation at 2 h and to cell cycling and apoptosis at 6 h. Several of the identified genes are particularly relevant to the biology of multiple myeloma and it was confirmed that ITF2357 also modulated their encoded proteins in different multiple myeloma cell lines. In particular, ITF2357 down-modulated the interleukin-6 receptor α (CD126) transcript and protein in both cell lines and freshly isolated patients’ cells, whereas it did not significantly modify interleukin-6 receptor β (CD130) expression. The decrease in CD126 expression was accompanied by decreased signaling by interleukin-6 receptor, as measured by STAT3 phosphorylation in the presence and absence of inter-leukin-6. Finally, the drug significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma. Conclusions ITF2357 inhibits several signaling pathways involved in myeloma cell growth and survival.

[1]  T. Cotter,et al.  Histone deacetylase activity in conjunction with E2F‐1 and p53 regulates Apaf‐1 expression in 661W cells and the retina , 2009, Journal of neuroscience research.

[2]  M. Pérez‐Andrés,et al.  Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease , 2009, International journal of cancer.

[3]  R. Bataille,et al.  IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop , 2008, The Journal of Immunology.

[4]  P. Tassone,et al.  In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor , 2008, British journal of haematology.

[5]  E. Brambilla,et al.  The new tumor suppressor genes ING: Genomic structure and status in cancer , 2008, International journal of cancer.

[6]  Francis J Giles,et al.  Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. , 2008, Cancer letters.

[7]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[8]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[9]  A. Burny,et al.  A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. , 2008, Trends in biochemical sciences.

[10]  F. Hofmann,et al.  The insulin‐like growth factor‐I receptor inhibitor NVP‐AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells , 2008, British Journal of Haematology.

[11]  J. Mendell.  miRiad Roles for the miR-17-92 Cluster in Development and Disease , 2008, Cell.

[12]  Rudolf Jaenisch,et al.  Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters , 2008, Cell.

[13]  J. Inazawa,et al.  POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17 , 2008, Oncogene.

[14]  T. Rème,et al.  Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications , 2007, Clinical Cancer Research.

[15]  K. Schroder,et al.  Histone deacetylase inhibitors decrease Toll‐like receptor‐mediated activation of proinflammatory gene expression by impairing transcription factor recruitment , 2007, Immunology.

[16]  L. Cuppini,et al.  The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells , 2007, Leukemia.

[17]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[18]  Lili Huang,et al.  Targeting histone deacetylases for the treatment of cancer and inflammatory diseases , 2006, Journal of cellular physiology.

[19]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[20]  S. Smale,et al.  Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. , 2006, Genes & development.

[21]  B. Levine,et al.  CD28-mediated regulation of multiple myeloma cell proliferation and survival. , 2005, Blood.

[22]  N. Tsuyama,et al.  Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals , 2005, Oncogene.

[23]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Munshi,et al.  Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. , 2005, Cancer research.

[25]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[26]  S. Bicciato,et al.  Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.

[27]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[28]  M. Gregor,et al.  Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. , 2005, Journal of hepatology.

[29]  P. Marks,et al.  Apoptotic and autophagic cell death induced by histone deacetylase inhibitors , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Hesson,et al.  RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family , 2004, Cancer Research.

[31]  J. Christensen,et al.  A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells , 2004, Clinical Cancer Research.

[32]  Hiroyuki Tagawa,et al.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.

[33]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone , 2003 .

[34]  Jacques Côté,et al.  The highly conserved and multifunctional NuA4 HAT complex. , 2004, Current opinion in genetics & development.

[35]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Golub,et al.  A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.

[37]  P. Richardson,et al.  Novel therapeutic approaches for multiple myeloma , 2003, Immunological reviews.

[38]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[39]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[40]  G. Fantuzzi,et al.  The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[42]  S. Saccani,et al.  Two Waves of Nuclear Factor κb Recruitment to Target Promoters , 2001, The Journal of experimental medicine.

[43]  D. Reinberg,et al.  RBP1 Recruits the mSIN3-Histone Deacetylase Complex to the Pocket of Retinoblastoma Tumor Suppressor Family Proteins Found in Limited Discrete Regions of the Nucleus at Growth Arrest , 2001, Molecular and Cellular Biology.

[44]  A. Protopopov,et al.  Isolation and chromosomal localization of a new human retinoblastoma binding protein 2 homologue 1a (RBBP2H1A) , 2000, European Journal of Human Genetics.

[45]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[46]  P. L. Bergsagel,et al.  Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.

[47]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[48]  Martine,et al.  CD28, a marker associated with tumoral expansion in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  S. Srinivasula,et al.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.

[50]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[51]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[52]  M. E. Ruaro,et al.  The growth arrest-specific gene, gas1, is involved in growth suppression , 1992, Cell.

[53]  P. Atadja,et al.  The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance , 2009, Nature Immunology.

[54]  Simmie L. Foster,et al.  Gene-specific control of the TLR-induced inflammatory response. , 2009, Clinical immunology.

[55]  T. Barbui,et al.  The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). , 2008, Leukemia.

[56]  Simmie L. Foster,et al.  Gene-specific control of inflammation by TLR-induced chromatin modifications , 2008, Nature.

[57]  G. Fantuzzi,et al.  The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo , 2005, Molecular medicine.

[58]  P. Tassone,et al.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. , 2005, Blood.

[59]  C. Li,et al.  Feature extraction and normalization algorithms for high‐density oligonucleotide gene expression array data , 2001, Journal of cellular biochemistry. Supplement.

[60]  A. Rolink,et al.  B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1 , 2001, Nature Immunology.

[61]  A. Kimchi,et al.  Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. , 1995, Genes & development.

[62]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.